Prevalence of cardiovascular risk factors (CRF) and metabolic syndrome (MS) in a cohort of HIV-infected patients in southern Spain. PREGO study

作者: M Gallego , F Oñate , A del Arco , J Roldan , M Grana

DOI: 10.1186/1758-2652-11-S1-P102

关键词:

摘要: riesgo cardiovascular (FRCV) y sindrome metabolico (SM) en pacientes con infeccion por el virus de la inmunodeficiencia humana (VIH). Metodos. Estudio observacional, multicentrico transversal todos los VIH atendidos forma ambulatoria 5 hospitales provincia Malaga entre marzo agosto 2007. A se realizo un cuestionario sobre FRCV, examen fisico analitica ayunas. El (RCV) a 10 anos mediante ecuacion Framingham diagnostico SM hizo funcion criterios del National Cholesterol Education Program. Resultados. Se incluyo 1.155 pacientes. 76,9% eran varones edad media fue 44,3 anos. 86,1% estaba tratamiento antirretroviral. La prevalencia FRCV siguiente: tabaco 59%, hipertrigliceridemia 38,2%, cHDL bajo 40,6%, hipertension arterial 10,6% diabetes mellitus 9,4%. 14,3% cumplia componentes mas frecuentes fueron (88,3%) colesterol unido lipoproteinas alta densidad (78,7%). Los tenian mayor RCV (el 10,9 frente al 5,6%; p < 0,0001). unico factor asociado (odds ratio = 4,7; intervalo confianza 95%, 4,6-4,8). Conclusiones. nuestro medio son muy frecuentes, cuales destaca consumo tabaco. es similar poblacion general espanola asocia RCV. desarrollo edad.

参考文章(44)
Class of antiretroviral drugs and the risk of myocardial infarction. The New England Journal of Medicine. ,vol. 356, pp. 1723- 1735 ,(2007) , 10.1056/NEJMOA062744
D. C. Rhew, M. Bernal, D. Aguilar, U. Iloeje, M. B. Goetz, Association between protease inhibitor use and increased cardiovascular risk in patients infected with human immunodeficiency virus: a systematic review. Clinical Infectious Diseases. ,vol. 37, pp. 959- 972 ,(2003) , 10.1086/378064
Denise L Jacobson, Alice M Tang, Donna Spiegelman, Ann M Thomas, Sally Skinner, Sherwood L Gorbach, Christine Wanke, Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). Journal of Acquired Immune Deficiency Syndromes. ,vol. 43, pp. 458- 466 ,(2006) , 10.1097/01.QAI.0000243093.34652.41
Murielle Mary-Krause, Laurent Cotte, Anne Simon, Maria Partisani, Dominique Costagliola, Clinical Epidemiology Group from the French Hospital Database, Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. ,vol. 17, pp. 2479- 2486 ,(2003) , 10.1097/00002030-200311210-00010
K. Mondy, E. T. Overton, J. Grubb, S. Tong, W. Seyfried, W. Powderly, K. Yarasheski, Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clinical Infectious Diseases. ,vol. 44, pp. 726- 734 ,(2007) , 10.1086/511679
Heidi M Crane, Stephen E Van Rompaey, Mari M Kitahata, Blood pressure and antiretroviral therapy. AIDS. ,vol. 21, pp. 1992- 1993 ,(2007) , 10.1097/QAD.0B013E3282EF7942
Giuseppe Vittorio L De Socio, Giustino Parruti, Tiziana Quirino, Elena Ricci, Giuseppe Schillaci, Beatrice Adriani, Patrizia Marconi, Marzia Franzetti, Canio Martinelli, Francesca Vichi, Giovanni Penco, Claudio Sfara, Giordano Madeddu, Paolo Bonfanti, CISAI Study Group, Identifying HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: Results from the SIMONE study Journal of Infection. ,vol. 57, pp. 33- 40 ,(2008) , 10.1016/J.JINF.2008.03.007
B. Isomaa, P. Almgren, T. Tuomi, B. Forsen, K. Lahti, M. Nissen, M.-R. Taskinen, L. Groop, Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome Diabetes Care. ,vol. 24, pp. 683- 689 ,(2001) , 10.2337/DIACARE.24.4.683
Andrew Carr, David A Cooper, Adverse effects of antiretroviral therapy The Lancet. ,vol. 356, pp. 1423- 1430 ,(2000) , 10.1016/S0140-6736(00)02854-3